
PubMed:32560744 / 630-897
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/32560744","sourcedb":"PubMed","sourceid":"32560744","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/32560744","text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19.","tracks":[{"project":"LitCovid-OGER-BB","denotations":[{"id":"T2","span":{"begin":230,"end":236},"obj":"CHEBI:36357"},{"id":"T3","span":{"begin":230,"end":236},"obj":"CHEBI:36357"},{"id":"T4","span":{"begin":258,"end":266},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"attributes":[{"subj":"T2","pred":"source","obj":"LitCovid-OGER-BB"},{"subj":"T3","pred":"source","obj":"LitCovid-OGER-BB"},{"subj":"T4","pred":"source","obj":"LitCovid-OGER-BB"}]},{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":60,"end":63},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma24890"},{"subj":"T1","pred":"source","obj":"LitCovid-PD-FMA-UBERON"}]},{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":60,"end":63},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"},{"subj":"T1","pred":"source","obj":"LitCovid-PD-UBERON"}]},{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":258,"end":266},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"subj":"T2","pred":"source","obj":"LitCovid-PD-MONDO"}]},{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":30,"end":31},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8","span":{"begin":60,"end":63},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T9","span":{"begin":94,"end":99},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T10","span":{"begin":188,"end":196},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"attributes":[{"subj":"T7","pred":"source","obj":"LitCovid-PD-CLO"},{"subj":"T8","pred":"source","obj":"LitCovid-PD-CLO"},{"subj":"T9","pred":"source","obj":"LitCovid-PD-CLO"},{"subj":"T10","pred":"source","obj":"LitCovid-PD-CLO"}]},{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":94,"end":99},"obj":"Chemical"},{"id":"T5","span":{"begin":128,"end":130},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"subj":"T4","pred":"source","obj":"LitCovid-PD-CHEBI"},{"subj":"T5","pred":"source","obj":"LitCovid-PD-CHEBI"}]},{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":0,"end":267},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T7","pred":"source","obj":"LitCovid-sentences"}]},{"project":"chenxin_473849_800_3","denotations":[{"id":"T1","span":{"begin":258,"end":266},"obj":"DP"}],"attributes":[{"subj":"T1","pred":"source","obj":"chenxin_473849_800_3"}]},{"project":"yangbin123xm_800_3","denotations":[{"id":"T2","span":{"begin":258,"end":266},"obj":"DP"}],"attributes":[{"subj":"T2","pred":"source","obj":"yangbin123xm_800_3"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-OGER-BB","color":"#dd93ec","default":true},{"id":"LitCovid-PD-FMA-UBERON","color":"#93ecc3"},{"id":"LitCovid-PD-UBERON","color":"#eca993"},{"id":"LitCovid-PD-MONDO","color":"#9397ec"},{"id":"LitCovid-PD-CLO","color":"#b1ec93"},{"id":"LitCovid-PD-CHEBI","color":"#ec93cb"},{"id":"LitCovid-sentences","color":"#93e5ec"},{"id":"chenxin_473849_800_3","color":"#ecd993"},{"id":"yangbin123xm_800_3","color":"#bf93ec"}]}]}}